Structural insights reveal interplay between LAG-3 homodimerization, ligand binding, and function
Open Access
- 14 March 2024
- journal article
- research article
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 121 (12)
Abstract
Lymphocyte activation gene-3 (LAG-3) is an inhibitory receptor expressed on activated T cells and an emerging immunotherapy target. Domain 1 (D1) of LAG-3, which has been purported to directly interact with major histocompatibility complex class II (MHCII) and fibrinogen-like protein 1 (FGL1), has been the major focus for the development of therapeutic antibodies that inhibit LAG-3 receptor-ligand interactions and restore T cell function. Here, we present a high-resolution structure of glycosylated mouse LAG-3 ectodomain, identifying that cis-homodimerization, mediated through a network of hydrophobic residues within domain 2 (D2), is critically required for LAG-3 function. Additionally, we found a previously unidentified key protein-glycan interaction in the dimer interface that affects the spatial orientation of the neighboring D1 domain. Mutation of LAG-3 D2 residues reduced dimer formation, dramatically abolished LAG-3 binding to both MHCII and FGL1 ligands, and consequentially inhibited the role of LAG-3 in suppressing T cell responses. Intriguingly, we showed that antibodies directed against D1, D2, and D3 domains are all capable of blocking LAG-3 dimer formation and MHCII and FGL-1 ligand binding, suggesting a potential allosteric model of LAG-3 function tightly regulated by dimerization. Furthermore, our work reveals unique epitopes, in addition to D1, that can be targeted for immunotherapy of cancer and other human diseases.Keywords
Funding Information
- Emerson Collective (162511)
- HHS | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases (T32AR069515-07)
- NIH (R01CA269898)
- NIH (R21AI163924-02)
- NIH (R37CA273333-01)
This publication has 43 references indexed in Scilit:
- Structure of a fully assembled tumor-specific T cell receptor ligated by pMHCCell, 2022
- Binding of LAG-3 to stable peptide-MHC class II limits T cell function and suppresses autoimmunity and anti-cancer immunityImmunity, 2022
- Fibrinogen-like Protein 1 Is a Major Immune Inhibitory Ligand of LAG-3Cell, 2019
- Generation of Fcabs targeting human and murine LAG-3 as building blocks for novel bispecific antibody therapeuticsMethods, 2018
- Eradication of Triple-Negative Breast Cancer Cells by Targeting Glycosylated PD-L1Cancer Cell, 2018
- cryoSPARC: algorithms for rapid unsupervised cryo-EM structure determinationNature Methods, 2017
- Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune RegulationImmunity, 2016
- Isolating and engineering human antibodies using yeast surface displayNature Protocols, 2006
- Fine Epitope Mapping of anti-Epidermal Growth Factor Receptor Antibodies Through Random Mutagenesis and Yeast Surface DisplayJournal of Molecular Biology, 2004
- Phenotypic analysis of the murine CD4-related glycoprotein, CD223 (LAG-3)European Journal of Immunology, 2002